Pradaxa oral pellets
通用名称
dabigatran etexilate
儿科标签批准日期
2021/6/21 0:00:00
特定指示/秒
Venous thromboembolic events (VTE) in pediatric patients aged 3 months to 11 years who have been treated with a parenteral anticoagulant for at least 5 days; To reduce the risk of recurrence of VTE in pediatric patients aged 3 months to 11 years who have been previously treated
标签更改摘要
- Safety and effectiveness of Pradaxa oral pellets for the treatment and the reduction in risk of recurrence of venous thromboembolism have been established in pediatric patients less than 12 years. Use for this indication is supported by evidence from adequate and well-controlled studies in pediatric patients. - Other age-appropriate pediatric formulations of dabigatran etexilate are available for pediatric patients aged 12 years and older for these indications. - Safety and effectiveness have not been established in pediatric patients with non-valvular atrial fibrillation or those who have undergone hip replacement surgery. - Information on dosing, adverse reactions, PK parameters, and clinical trials. - Postmarketing study. - Postmarketing study. - New dosage form.
治疗类别
Anti-Coagulant
立法类型
PREA + BPCA
产品说明书链接
书号
5.0 4.0 3.0 2.0 1.0
研究年龄
6 MONTHS - 18 YEARS 0 YEARS - 17 YEARS 41 DAYS - 24 WEEKS 1 YEARS - 11 YEARS 13 YEARS - 17 YEARS
学习类型
Safety,Pharmacokinetic,Pharmacodynamic Efficacy,Safety,Pharmacokinetic,Pharmacodynamic Safety,Pharmacokinetic,Pharmacodynamic,Tolerability Safety,Pharmacokinetic,Pharmacodynamic,Tolerability Safety,Pharmacokinetic,Pharmacodynamic,Tolerability
研究设计
Multicenter,Open-Label,Phase 2,Phase 3,Prospective,Single-arm Multicenter,Randomized,Active Comparator,Parallel Group,Open-Label,Phase 2,Phase 3,Non-Inferiority Multicenter,Open-Label,Single-dose,Phase 2,Non-Randomized,Single-arm Multicenter,Open-Label,Single-dose,Phase 2,Non-Randomized,Single-arm Multicenter,Open-Label,Phase 2,Non-Randomized,Single-arm
登记的患者
231 328 10 20 9
患者分析
213 267 8 18 9
中心的数量
62 65 4 8 4
国家数量
22 26 3 6 1
西班牙裔拉美裔/拉丁裔总计
9 11 0 N/A N/A
非西班牙裔/非拉丁裔总人数
203 255 7 N/A N/A
总数#种族不明
1 1 1 N/A N/A
亚裔学生总数
7 13 0 4 0
黑人总数
8 4 1 0 0
白人总数
194 245 7 14 9
夏威夷或太平洋岛民总数
0 0 0 0 0
美洲印第安人/阿拉斯加本地人总数
0 0 0 0 0
其他种族总计
3 2 0 0 0
未知种族总数
1 3 0 0 0
国家
United States,Austria,Belgium,Brazil,Canada,Czech Republic,Denmark,France,Germany,Hungary,Israel,Italy,Lithuania,Mexico,Norway,Russian Federation,Sweden,Switzerland,Taiwan,Thailand,Turkey,Ukraine United States,Argentina,Austria,Belgium,Brazil,Canada,Czech Republic,Denmark,Finland,France,Germany,Greece,Hungary,Israel,Italy,Lithuania,Mexico,Norway,Russian Federation,Spain,Sweden,Switzerland,Taiwan,Thailand,Turkey,Ukraine Canada,France,Russian Federation Canada,Italy,Lithuania,Russian Federation,Switzerland,Thailand Canada
免责声明:以上所展示的信息由企业自行提供,内容的真实性、准确性和合法性由发布企业负责,医药网对此不承担任何责任。
相关链接:国家药品监督管理局| 国家中医药管理局| SDA药品评审中心| 医加医疗器械| 膏药生产厂家| 爱视立眼贴
专业提供药品信息、药品招商、药品代理、保健品招商、医药原料采购供应的中国药品信息网站平台
版权所有 © 2003-2028 盗冒必究  客服热线:0575-83552251 / 13754370441  QQ客服:药品信息客服
浙ICP备16010490号-2 增值电信业务经营许可证:浙B2-20220931 互联网药品信息服务资格证书编号:(浙)-经营性2023-0215 浙公网安备:33068302000535
 医药代理商群1:药药网药品采购交流医药代理商群2:药药网药品采购交流2医药代理商群3:药药网药品采购交流3